JP2011037872A5 - - Google Patents

Download PDF

Info

Publication number
JP2011037872A5
JP2011037872A5 JP2010223922A JP2010223922A JP2011037872A5 JP 2011037872 A5 JP2011037872 A5 JP 2011037872A5 JP 2010223922 A JP2010223922 A JP 2010223922A JP 2010223922 A JP2010223922 A JP 2010223922A JP 2011037872 A5 JP2011037872 A5 JP 2011037872A5
Authority
JP
Japan
Prior art keywords
ser
cys
gly
trp
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010223922A
Other languages
English (en)
Japanese (ja)
Other versions
JP5876644B2 (ja
JP2011037872A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2011037872A publication Critical patent/JP2011037872A/ja
Publication of JP2011037872A5 publication Critical patent/JP2011037872A5/ja
Application granted granted Critical
Publication of JP5876644B2 publication Critical patent/JP5876644B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2010223922A 2003-03-03 2010-10-01 ＨＧＦレセプター（ｃＭｅｔ）を特異的に結合するペプチドおよびその使用 Expired - Lifetime JP5876644B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45158803P 2003-03-03 2003-03-03
US60/451,588 2003-03-03

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2006509035A Division JP5466350B2 (ja) 2003-03-03 2004-03-03 ＨＧＦレセプター（ｃＭｅｔ）を特異的に結合するペプチドおよびその使用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014068150A Division JP6216280B2 (ja) 2003-03-03 2014-03-28 ＨＧＦレセプター（ｃＭｅｔ）を特異的に結合するペプチドおよびその使用

Publications (3)

Publication Number Publication Date
JP2011037872A JP2011037872A (ja) 2011-02-24
JP2011037872A5 true JP2011037872A5 (OSRAM) 2011-09-15
JP5876644B2 JP5876644B2 (ja) 2016-03-02

Family

ID=32962606

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2006509035A Expired - Lifetime JP5466350B2 (ja) 2003-03-03 2004-03-03 ＨＧＦレセプター（ｃＭｅｔ）を特異的に結合するペプチドおよびその使用
JP2010223922A Expired - Lifetime JP5876644B2 (ja) 2003-03-03 2010-10-01 ＨＧＦレセプター（ｃＭｅｔ）を特異的に結合するペプチドおよびその使用
JP2014068150A Expired - Lifetime JP6216280B2 (ja) 2003-03-03 2014-03-28 ＨＧＦレセプター（ｃＭｅｔ）を特異的に結合するペプチドおよびその使用
JP2016137140A Expired - Lifetime JP6374913B2 (ja) 2003-03-03 2016-07-11 ＨＧＦレセプター（ｃＭｅｔ）を特異的に結合するペプチドおよびその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2006509035A Expired - Lifetime JP5466350B2 (ja) 2003-03-03 2004-03-03 ＨＧＦレセプター（ｃＭｅｔ）を特異的に結合するペプチドおよびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014068150A Expired - Lifetime JP6216280B2 (ja) 2003-03-03 2014-03-28 ＨＧＦレセプター（ｃＭｅｔ）を特異的に結合するペプチドおよびその使用
JP2016137140A Expired - Lifetime JP6374913B2 (ja) 2003-03-03 2016-07-11 ＨＧＦレセプター（ｃＭｅｔ）を特異的に結合するペプチドおよびその使用

Country Status (13)

Country Link
US (6) US20050214859A1 (OSRAM)
EP (4) EP2949658B1 (OSRAM)
JP (4) JP5466350B2 (OSRAM)
AU (2) AU2004217894B2 (OSRAM)
CA (1) CA2517939C (OSRAM)
CY (1) CY1120683T1 (OSRAM)
DK (2) DK2949658T3 (OSRAM)
ES (3) ES2557286T3 (OSRAM)
HU (1) HUE039154T2 (OSRAM)
PL (2) PL1944312T3 (OSRAM)
PT (1) PT2949658T (OSRAM)
SI (1) SI2949658T1 (OSRAM)
WO (1) WO2004078778A2 (OSRAM)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US20050100963A1 (en) 2002-03-01 2005-05-12 Dyax Corporation KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
EP2949658B1 (en) * 2003-03-03 2018-08-08 Dyax Corp. Peptides that specifically bind HGF receptor (cMet) and uses thereof
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
NO20034350D0 (no) * 2003-09-29 2003-09-29 Amersham Health As Optisk avbilding av kolorektal kreft
US20060008844A1 (en) * 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
JP2008516629A (ja) * 2004-10-20 2008-05-22 ペアス インスティテュート アーベー 肝細胞増殖因子（ｈｇｆ）の生物活性に関する評価
WO2008005531A2 (en) * 2006-07-07 2008-01-10 Washington State University Research Foundation C-met receptor regulation by angiotensin iv (at4) receptor ligands
US8236761B2 (en) 2006-07-07 2012-08-07 Washington State University Research Foundation C-Met receptor regulation by angiotensin IV (AT4) receptor ligands
WO2008094275A1 (en) * 2007-01-30 2008-08-07 New York University Peptides for treatment of conditions associated with nitric oxide
CA2685553C (en) * 2007-05-16 2017-03-28 Ge Healthcare As Peptide imaging agents
GB0718967D0 (en) * 2007-09-28 2007-11-07 Ge Healthcare Ltd Peptide imaging agents
GB0718957D0 (en) * 2007-09-28 2007-11-07 Ge Healthcare Ltd Optical imaging agents
US20100196272A1 (en) 2009-01-30 2010-08-05 Neoprobe Corporation Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran
GB0918321D0 (en) 2009-10-20 2009-12-02 Ge Healthcare As Cyclic peptide synthesis
EP2496948B1 (en) 2009-11-05 2018-01-10 University of Virginia Patent Foundation Compositions and methods for detecting plectin-1 as a biomarker for cancer
GB201013808D0 (en) * 2010-08-18 2010-09-29 Ge Healthcare Ltd Peptide radiotracer compositions
GB201103696D0 (en) 2011-03-04 2011-04-20 Ge Healthcare Ltd Technetium labelled peptides
GB201116733D0 (en) 2011-09-28 2011-11-09 Ge Healthcare As Peptide margin imaging agents
GB201116862D0 (en) 2011-09-30 2011-11-09 Ge Healthcare As Infusion imaging method
GB201121914D0 (en) 2011-12-20 2012-02-01 Ge Healthcare Ltd Method for patient selection
WO2014074907A1 (en) * 2012-11-09 2014-05-15 Indi Molecular, Inc. C-met-specific capture agents, compositions, and methods of using and making
RU2679889C2 (ru) 2013-04-18 2019-02-14 Армо Байосайенсиз, Инк. Способы применения интерлейкина-10 для лечения заболеваний и расстройств
US9823255B2 (en) 2013-06-17 2017-11-21 Armo Biosciences, Inc. Method for assessing protein identity and stability
CA2920835A1 (en) 2013-08-20 2015-02-26 Anutra Medical, Inc. Syringe fill system and method
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
WO2015031316A1 (en) 2013-08-30 2015-03-05 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
KR102178945B1 (ko) 2013-10-28 2020-11-13 엔지엠 바이오파마슈티컬스, 아이엔씨. 암 모델 및 관련 방법
CN105848674A (zh) 2013-11-11 2016-08-10 阿尔莫生物科技股份有限公司 将白细胞介素-10用于治疗疾病和病症的方法
GB201322456D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
CN106573072A (zh) 2014-06-02 2017-04-19 阿尔莫生物科技股份有限公司 降低血清胆固醇的方法
USD750768S1 (en) 2014-06-06 2016-03-01 Anutra Medical, Inc. Fluid administration syringe
USD774182S1 (en) 2014-06-06 2016-12-13 Anutra Medical, Inc. Anesthetic delivery device
USD763433S1 (en) 2014-06-06 2016-08-09 Anutra Medical, Inc. Delivery system cassette
US10806803B2 (en) 2014-07-17 2020-10-20 Ohio State Innovation Foundation Compositions for targeting macrophages and other CD206 high expressing cells and methods of treating and diagnosis
US20170240883A1 (en) * 2014-08-11 2017-08-24 Miti Biosystems GmbH Cyclic peptides expressed by a genetic package
US20170343557A1 (en) * 2014-09-22 2017-11-30 Kenneth Kun-Yu WU Use of 5-methoxytryptophan as diagnostic agent of inflammatory diseases
WO2016060996A2 (en) 2014-10-14 2016-04-21 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
MX2017004983A (es) 2014-10-22 2017-11-13 Armo Biosciences Inc Metodos para usar interleucina 10 para tratar enfermedades y trastornos.
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
JP7121496B2 (ja) 2015-05-28 2022-08-18 アルモ・バイオサイエンシーズ・インコーポレイテッド 癌治療で使用するためのペグ化インターロイキン－１０
US20190307849A1 (en) 2015-05-29 2019-10-10 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
SI3307296T1 (sl) 2015-06-15 2022-04-29 The Board of Trustees of the Leland Stanford Junior University Office of the General Counsel TIMP2 za uporabo pri zdravljenju s starostjo povezanih stanj
JP7053453B2 (ja) 2015-08-25 2022-04-12 アルモ・バイオサイエンシーズ・インコーポレイテッド 疾患及び障害を治療するためのインターロイキン１０の使用方法
CN109563144B (zh) * 2016-06-01 2023-03-28 雅斯娜 化合物
US20190151483A1 (en) 2016-07-25 2019-05-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Methods of making 18f-labeled precursors and peptides, labeled c-met binding peptides, and methods of use thereof
WO2018052002A1 (ja) * 2016-09-13 2018-03-22 第一三共株式会社 Ｔｈｒｏｍｂｏｓｐｏｎｄｉｎ １結合ペプチド
US11739163B2 (en) 2016-09-29 2023-08-29 Aebi Ltd. Therapeutic multi-targeting constructs and uses thereof
WO2018068060A1 (en) 2016-10-07 2018-04-12 Navidea Biopharmaceuticals, Inc. Compounds and methods for diagnosis and treatment of viral infections
GB201804835D0 (en) * 2018-03-26 2018-05-09 Ge Healthcare As Formulation and method of preparation
CN114222592A (zh) * 2019-06-14 2022-03-22 爱丁堡分子成像有限公司 化合物和使用方法
CA3157605A1 (en) 2019-11-13 2021-05-20 Volker Schellenberger Barcoded xten polypeptides and compositions thereof, and methods for making and using the same
TW202509086A (zh) * 2021-03-22 2025-03-01 日商肽夢想股份有限公司 c－Met蛋白質結合肽複合物
JP7162853B1 (ja) 2021-07-02 2022-10-31 ペプチスター株式会社 液相ペプチド合成用担体結合ペプチドの分析方法
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
US20250222027A1 (en) 2022-04-01 2025-07-10 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
WO2023225273A1 (en) 2022-05-20 2023-11-23 Navidea Biopharmaceuticals, Inc. Cd206 targeted drug delivery vehicles carrying novel bisphosphonate drug payloads via a degradable linker

Family Cites Families (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4180646A (en) 1975-01-28 1979-12-25 Alza Corporation Novel orthoester polymers and orthocarbonate polymers
US4093709A (en) 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4131648A (en) 1975-01-28 1978-12-26 Alza Corporation Structured orthoester and orthocarbonate drug delivery devices
US4391797A (en) 1977-01-05 1983-07-05 The Children's Hospital Medical Center Systems for the controlled release of macromolecules
US4718433A (en) 1983-01-27 1988-01-12 Feinstein Steven B Contrast agents for ultrasonic imaging
DE3313946A1 (de) 1983-04-15 1984-10-18 Schering AG, 1000 Berlin und 4709 Bergkamen Mikropartikel und gasblaeschen enthaltende ultraschall-kontrastmittel
DE3834705A1 (de) 1988-10-07 1990-04-12 Schering Ag Ultraschallkontrastmittel aus gasblaeschen und fettsaeure enthaltenden mikropartikeln
DE3313947A1 (de) 1983-04-15 1984-10-18 Schering AG, 1000 Berlin und 4709 Bergkamen Mikropartikel und gasblaeschen enthaltende ultraschall-kontrastmittel
US4900540A (en) 1983-06-20 1990-02-13 Trustees Of The University Of Massachusetts Lipisomes containing gas for ultrasound detection
US4899755A (en) 1985-05-08 1990-02-13 The General Hospital Corporation Hepatobiliary NMR contrast agents
MX174467B (es) 1986-01-23 1994-05-17 Squibb & Sons Inc 1,4,7-triscarboximetil-1,4,7,10-tetraazaciclodo decano substituido en 1 y compuestos analogos
US5021556A (en) 1987-07-22 1991-06-04 Neorx Corporation Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides
US4844882A (en) 1987-12-29 1989-07-04 Molecular Biosystems, Inc. Concentrated stabilized microbubble-type ultrasonic imaging agent
IE61591B1 (en) 1987-12-29 1994-11-16 Molecular Biosystems Inc Concentrated stabilized microbubble-type ultrasonic imaging agent and method of production
US5075099A (en) 1988-05-31 1991-12-24 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
EP0489869B1 (en) 1989-08-28 1998-11-11 The General Hospital Corporation Hydroxy-aryl metal chelates for diagnostic nmr imaging
US5118797A (en) 1989-08-28 1992-06-02 E. R. Squibb & Sons, Inc. Rhenium tris dioxime complexes
US5585112A (en) * 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US6146657A (en) * 1989-12-22 2000-11-14 Imarx Pharmaceutical Corp. Gas-filled lipid spheres for use in diagnostic and therapeutic applications
US5305757A (en) 1989-12-22 1994-04-26 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
US5773024A (en) * 1989-12-22 1998-06-30 Imarx Pharmaceutical Corp. Container with multi-phase composition for use in diagnostic and therapeutic applications
US5469854A (en) 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US5123414A (en) 1989-12-22 1992-06-23 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5230882A (en) 1989-12-22 1993-07-27 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5871959A (en) * 1989-12-27 1999-02-16 The United States Of America As Represented By The Department Of Health And Human Services Method of producing hepatocycte growth factor/scatter factor and related cell lines
CA2034042C (en) 1990-01-18 1999-08-17 Adrian D. Nunn Boronic acid adducts of rhenium dioxime and technetium-99m dioxime complexes containing a biochemically active group
US5556610A (en) 1992-01-24 1996-09-17 Bracco Research S.A. Gas mixtures useful as ultrasound contrast media, contrast agents containing the media and method
US5445813A (en) 1992-11-02 1995-08-29 Bracco International B.V. Stable microbubble suspensions as enhancement agents for ultrasound echography
IN172208B (OSRAM) 1990-04-02 1993-05-01 Sint Sa
US5578292A (en) 1991-11-20 1996-11-26 Bracco International B.V. Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof
US5183653A (en) 1990-04-13 1993-02-02 E. R. Squibb & Sons, Inc. Boronic acid adducts of metal dioxime complexes useful in labelling proteins and other amine-containing compounds
US5137928A (en) 1990-04-26 1992-08-11 Hoechst Aktiengesellschaft Ultrasonic contrast agents, processes for their preparation and the use thereof as diagnostic and therapeutic agents
AU636481B2 (en) 1990-05-18 1993-04-29 Bracco International B.V. Polymeric gas or air filled microballoons usable as suspensions in liquid carriers for ultrasonic echography
US5173298A (en) 1990-09-27 1992-12-22 Allergan, Inc. Nonaqueous fluorinated drug delivery vehicle suspensions
US5367080A (en) 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
ATE188387T1 (de) 1991-02-08 2000-01-15 Diatide Inc Technetium-99m markierte polypeptide zur bildformung
US5849261A (en) 1991-02-08 1998-12-15 Diatide, Inc. Radiolabeled vasoactive intestinal peptides for diagnosis and therapy
US5965107A (en) 1992-03-13 1999-10-12 Diatide, Inc. Technetium-99m labeled peptides for imaging
EP0536350B1 (en) 1991-02-22 2002-08-07 American Cyanamid Company Identification of a novel human receptor tyrosine kinase gene
GB9106686D0 (en) 1991-03-28 1991-05-15 Hafslund Nycomed As Improvements in or relating to contrast agents
GB9106673D0 (en) 1991-03-28 1991-05-15 Hafslund Nycomed As Improvements in or relating to contrast agents
WO1992021382A1 (en) 1991-06-03 1992-12-10 Holmes, Michael, John Improvements in or relating to contrast agents
DK0593624T3 (da) 1991-07-05 1997-05-20 Nycomed Imaging As Forbedringer af eller i relation til kontrastmidler
US5808091A (en) 1991-10-29 1998-09-15 Bracco International B.V. Rhenium and technetium complexes containing a hypoxia localizing moiety
GB9200391D0 (en) 1992-01-09 1992-02-26 Nycomed As Improvements in or relating to contrast agents
GB9200387D0 (en) 1992-01-09 1992-02-26 Nycomed As Improvements in or relating to contrast agents
GB9200388D0 (en) 1992-01-09 1992-02-26 Nycomed As Improvements in or relating to contrast agents
IL104084A (en) 1992-01-24 1996-09-12 Bracco Int Bv Long-lasting aqueous suspensions of pressure-resistant gas-filled microvesicles their preparation and contrast agents consisting of them
US5861301A (en) 1992-02-20 1999-01-19 American Cayanamid Company Recombinant kinase insert domain containing receptor and gene encoding same
US5877289A (en) 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5316921A (en) * 1992-05-18 1994-05-31 Genentech, Inc. Single-chain hepatocyte growth factor variants
CA2118012A1 (en) * 1992-05-18 1993-11-25 Paul J. Godowski Hepatocyte growth factor variants
EP0656069A4 (en) * 1992-08-10 1996-07-10 Cambridge Neuroscience Inc CELL PROLIFERATION INHIBITORS, THEIR PRODUCTION AND USE.
ATE348110T1 (de) 1992-10-28 2007-01-15 Genentech Inc Hvegf rezeptor als vegf antagonist
US5608110A (en) 1993-06-15 1997-03-04 Bracco International B.V. Heteroatom-bearing ligands and metal complexes thereof
PL312387A1 (en) 1993-07-02 1996-04-15 Molecular Biosystems Inc Proteinous microbeads of encapsulated non-dissolving gas and method of making them and their application as ultrasonic visualisation medium
JPH09500140A (ja) 1993-07-19 1997-01-07 レゾリューション・ファーマスーティカルズ・インコーポレーテッド Ｎ▲下３▼ｓ立体配置を有するヒドラジノ型放射性核種キレート形成剤
US5798091A (en) 1993-07-30 1998-08-25 Alliance Pharmaceutical Corp. Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement
US5574140A (en) 1993-09-03 1996-11-12 Resolution Pharmaceutical Inc. Hydrazino-type N2 S2 chelators
HU225495B1 (en) 1993-12-15 2007-01-29 Bracco Research Sa Gas mixtures useful as ultrasound contrast media
GB9402867D0 (en) 1994-02-15 1994-04-06 Nycomed Imaging As Improvements in or relating to contrast agents
DK0751992T3 (da) * 1994-03-08 2006-03-06 Human Genome Sciences Inc Karendotelvækstfaktor 2
JP2891647B2 (ja) 1994-03-11 1999-05-17 株式会社日本触媒 有機スルフィド化合物及びその製造方法
US5770565A (en) 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
US5582814A (en) 1994-04-15 1996-12-10 Metasyn, Inc. 1-(p-n-butylbenzyl) DTPA for magnetic resonance imaging
CN1148813A (zh) 1994-04-20 1997-04-30 耐克麦德瑟鲁塔公司 造影剂
US5707624A (en) * 1994-06-03 1998-01-13 The Regents Of The University Of Michigan Treatment of Kaposi's sarcoma by inhibition of scatter factor
US5650135A (en) 1994-07-01 1997-07-22 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive localization of a light-emitting conjugate in a mammal
US5662885A (en) 1994-07-22 1997-09-02 Resolution Pharmaceuticals Inc. Peptide derived radionuclide chelators
GB9417941D0 (en) 1994-09-06 1994-10-26 Nycomed Imaging As Improvements in or relating to contrast agents
US5556939A (en) 1994-10-13 1996-09-17 Merck Frosst Canada, Inc. TC or RE radionuclide labelled chelate, hexapeptide complexes useful for diagnostic or therapeutic applications
US6645933B1 (en) * 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
US6221839B1 (en) * 1994-11-14 2001-04-24 Helsinki University Licensing Ltd. Oy FIt4 ligand and methods of use
US6403088B1 (en) * 1995-08-01 2002-06-11 Helsinki University Licensing, Ltd. Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3)
US6245530B1 (en) * 1995-08-01 2001-06-12 Ludwig Institute For Cancer Research Receptor ligand
US6333021B1 (en) 1994-11-22 2001-12-25 Bracco Research S.A. Microcapsules, method of making and their use
DE4445065A1 (de) 1994-12-07 1996-06-13 Diagnostikforschung Inst Verfahren zur In-vivo-Diagnostik mittels NIR-Strahlung
IL116328A (en) 1994-12-16 1999-09-22 Bracco Research Sa Frozen suspension of gas microbubbles in frozen aqueous carrier for use as contrast agent in ultrasonic imaging
TW319763B (OSRAM) 1995-02-01 1997-11-11 Epix Medical Inc
GB9502065D0 (en) 1995-02-02 1995-03-22 Nycomed Imaging As Contrast media
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US6521211B1 (en) 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
JP4215820B2 (ja) 1995-06-07 2009-01-28 イマアーレクス・フアーマシユーチカル・コーポレーシヨン 診断的および治療的使用のための新規な標的化組成物
US6361946B1 (en) * 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
DK0848755T4 (da) 1995-09-08 2011-05-23 Genentech Inc VEGF relateret protein
WO1997017442A1 (en) 1995-11-08 1997-05-15 Immunex Corporation Flk-1 binding protein
US5837680A (en) 1996-02-16 1998-11-17 Children's Medical Center Corporation Pharmaceutical compositions comprising troponin subunits, fragments and analogs thereof and methods of their use to inhibit angiogenesis
NZ331509A (en) 1996-02-19 2000-04-28 Nycomed Imaging As Aqueous dispersions of stabilised gas microbubbles and their use as contrast agents
KR20060025233A (ko) 1996-04-01 2006-03-20 에픽스 메디칼, 인코포레이티드 생체활성화 진단용 영상 콘트라스트 제제
IL128345A (en) 1996-08-02 2003-06-24 Amersham Health As Enhanced contrast agent for ultrasound imaging of the liver
TW320761B (en) * 1996-10-03 1997-11-21 Mos Electronics Taiwan Inc Manufacturing method of high density DRAM with cylindrical stack capacitor
CZ140999A3 (cs) 1996-10-21 1999-09-15 Nycomed Imaging As Směsný prostředek pro použití jako kontrastní činidlo
EP0991427A2 (en) 1996-10-28 2000-04-12 Marsden, John Christopher Improvements in or relating to diagnostic/therapeutic agents
GB9708265D0 (en) 1997-04-24 1997-06-18 Nycomed Imaging As Contrast agents
WO1998018497A2 (en) 1996-10-28 1998-05-07 Nycomed Imaging As Contrast agents
CZ149499A3 (cs) * 1996-10-28 1999-09-15 Nycomed Imaging As Diagnostický a/nebo léčebný prostředek
WO1998018498A2 (en) 1996-10-28 1998-05-07 Marsden, John, Christopher Improvements in or relating to diagnostic/therapeutic agents
US6331289B1 (en) * 1996-10-28 2001-12-18 Nycomed Imaging As Targeted diagnostic/therapeutic agents having more than one different vectors
WO1998018501A2 (en) 1996-10-28 1998-05-07 Marsden, John, Christopher Improvements in or relating to diagnostic/therapeutic agents
WO1998018496A2 (en) 1996-10-28 1998-05-07 Nycomed Imaging As Contrast agents
US6261537B1 (en) * 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
US7125714B2 (en) * 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
US5919967A (en) 1997-04-11 1999-07-06 Epix Medical, Inc. Process for synthesizing phosphodiesters
DE19717904A1 (de) 1997-04-23 1998-10-29 Diagnostikforschung Inst Säurelabile und enzymatisch spaltbare Farbstoffkonstrukte zur Diagnostik mit Nahinfrarotlicht und zur Therapie
US5886142A (en) 1997-05-20 1999-03-23 Thomas Jefferson University Radiolabeled thrombus imaging agents
US6245318B1 (en) 1997-05-27 2001-06-12 Mallinckrodt Inc. Selectively binding ultrasound contrast agents
IL120943A (en) 1997-05-29 2004-03-28 Univ Ben Gurion A system for administering drugs through the skin
GB9712525D0 (en) 1997-06-16 1997-08-20 Nycomed Imaging As Method
DE69838334T2 (de) * 1997-06-18 2008-06-12 Merck & Co., Inc. (A New Jersey Corp.) Kdr, ein menschlicher tyrosin kinase rezeptor
JP2001518523A (ja) 1997-10-02 2001-10-16 エピックス メディカル， インコーポレイテッド インターベンショナル療法をモニタリングするためのコントラスト増強型診断的画像化方法
EP1037994A1 (en) 1997-12-09 2000-09-27 Children's Medical Center Corporation Peptide antagonists of vascular endothelial growth factor
US6165458A (en) 1997-12-26 2000-12-26 Pharmaderm Laboratories Ltd. Composition and method for dermal and transdermal administration of a cytokine
AU753196B2 (en) 1998-02-09 2002-10-10 Bracco Research S.A. Targeted delivery of biologically active media
WO1999040947A2 (en) 1998-02-11 1999-08-19 Resolution Pharmaceuticals Inc. Angiogenesis targeting molecules
US20020136721A1 (en) * 1998-02-17 2002-09-26 Schwall Ralph H. Hepatocyte growth factor receptor antagonists and uses thereof
KR20010042288A (ko) 1998-03-31 2001-05-25 블레어 큐. 퍼거슨 신생혈관 형성 질환의 영상화용 약제
US6093382A (en) 1998-05-16 2000-07-25 Bracco Research Usa Inc. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
AU1908000A (en) 1998-11-06 2000-05-29 Basf Aktiengesellschaft Inhibition of the formation of vascular hyperpermeability
US6312665B1 (en) 1998-12-21 2001-11-06 Generex Pharmaceuticals Incorporated Aerosol formulations for buccal and pulmonary application
AU3249300A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. 47 human secreted proteins
AU3517000A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. 50 human secreted proteins
US20090087878A9 (en) * 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
US6294525B1 (en) 1999-09-01 2001-09-25 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
GB9928950D0 (en) 1999-12-07 2000-02-02 Metris Therapeutics Limited Binding protein
AU783683B2 (en) * 2000-01-18 2005-11-24 Vegenics Limited VEGF-D/VEGF-C/VEGF peptidomimetic inhibitor
US7740841B1 (en) 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
JP2003528824A (ja) * 2000-02-04 2003-09-30 スプラテック ファーマ インコーポレイティド 血管内皮成長因子受容体のためのリガンド
JP4981229B2 (ja) 2000-02-25 2012-07-18 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ ハイブリッド血管内皮成長因子ＤＮＡｓおよびタンパク質に関与する物質および方法
US20020102260A1 (en) * 2000-03-02 2002-08-01 Marc Achen Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissue
CA2401665A1 (en) 2000-03-02 2001-09-07 Ludwig Institute For Cancer Research Methods for treating, screening for, and detecting cancers expressing vascular endothelial growth factor d
US6769080B2 (en) * 2000-03-09 2004-07-27 Texas Instruments Incorporated Scan circuit low power adapter with counter
EP1265635A1 (en) 2000-03-22 2002-12-18 Glaxo Group Limited Pharmaceutical comprising an agent that blocks the cell cycle and an antibody
US20010031485A1 (en) 2000-03-22 2001-10-18 Sibtech, Inc. Recombinant proteins containing Shiga-like toxin and vascular endothelial growth factor fragments
JP2003528632A (ja) * 2000-03-31 2003-09-30 インスティティ・パスツール 血管内皮成長因子（ｖｅｇｆ）−媒介性脈管形成を阻害するペプチド、該ペプチドをエンコードするポリヌクレオチド及びその使用方法
US20050100991A1 (en) * 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
WO2001083693A2 (en) 2000-04-28 2001-11-08 Glaxo Group Limited Compounds having affinity for the vascular endothelial growth factor receptor-2 (vegfr-2) and associated uses
AU2001264565B2 (en) 2000-05-03 2006-12-07 Vegenics Limited A method for activating only the vascular endothelial growth factor receptor-3 and uses thereof
KR100457350B1 (ko) * 2000-06-01 2004-11-16 이경림 ＩｇＥ-의존적 히스타민 방출인자(ＨＲＦ)의 수용체,ＨＲＦ 결합 펩타이드 및 그들을 코딩하는 핵산, 및그들의 용도
EP1166798A1 (en) 2000-06-23 2002-01-02 Schering Aktiengesellschaft Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/ Tie receptor function and their use
ATE363291T1 (de) 2000-06-23 2007-06-15 Bayer Schering Pharma Ag Zusammensetzungen, die mit vegf/vegf und angiopoietin/tie rezeptor-funktionen interferieren
EP1166799A1 (en) 2000-06-28 2002-01-02 Schering Aktiengesellschaft Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/Tie receptor function and their use (II)
AU2001276934A1 (en) 2000-07-18 2002-02-05 Joslin Diabetes Center Inc. Methods of modulating fibrosis
US20020091082A1 (en) * 2000-09-13 2002-07-11 Aiello Lloyd P. Methods of modulating symptoms of hypertension
FR2814744B1 (fr) * 2000-10-04 2002-11-29 Commissariat Energie Atomique Cyclopeptides, leur procede de preparation et leur utilisation comme inhibiteur ou activateur de l'angiogenese
US20030082103A1 (en) * 2000-10-11 2003-05-01 Targesome, Inc. Targeted therapeutic lipid constructs having cell surface targets
US7611711B2 (en) 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
CA2435503C (en) 2001-01-19 2011-02-22 Ludwig Institute For Cancer Research Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
CA2444624A1 (en) 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
JP2005518185A (ja) * 2001-06-04 2005-06-23 キュラジェン コーポレイション 新規タンパク質およびそれをコード化する核酸
CA2450921A1 (en) * 2001-06-22 2003-01-03 Incyte Genomics, Inc. Protein modification and maintenance molecules
AU2002362461A1 (en) 2001-10-01 2003-04-14 Targesome, Inc. Targeted therapeutic lipid constructs having cell surface targets
US6766860B2 (en) * 2002-02-22 2004-07-27 Globalsantafe Corporation Multi-activity offshore drilling facility having a support for tubular string
US7794693B2 (en) * 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US7211240B2 (en) * 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US20040033949A1 (en) 2002-05-06 2004-02-19 Genentech, Inc. Use of VEGF for treating bone defects
EP2949658B1 (en) * 2003-03-03 2018-08-08 Dyax Corp. Peptides that specifically bind HGF receptor (cMet) and uses thereof
KR101658439B1 (ko) * 2005-12-09 2016-09-21 브라코 스위스 에스.에이. 표적화 벡터-포스포리피드 컨쥬게이트
EP2618146B1 (en) * 2008-02-25 2015-06-17 Nestec S.A. Drug selection for breast cancer therapy using antibody-based arrays
US9801473B2 (en) 2012-09-13 2017-10-31 Kids Ii, Inc. Play yard with removable liner
WO2015005839A1 (en) 2013-07-12 2015-01-15 Telefonaktiebolaget L M Ericsson (Publ) Method for enabling control of data packet flows belonging to different access technologies

Similar Documents

Publication Publication Date Title
JP2011037872A5 (OSRAM)
Gautam et al. Tumor homing peptides as molecular probes for cancer therapeutics, diagnostics and theranostics
JP2015530404A5 (OSRAM)
Rafferty et al. Peptide therapeutics and the pharmaceutical industry: barriers encountered translating from the laboratory to patients
JP2009519013A5 (OSRAM)
Sparr et al. Syntheses, Receptor Bindings, in vitro and in vivo Stabilities and Biodistributions of DOTA‐Neurotensin (8–13) Derivatives Containing β‐Amino Acid Residues–A Lesson about the Importance of Animal Experiments
WO2022021528A1 (zh) 一种ace2受体靶向核素多肽探针及其制备方法和应用
CN106831945B (zh) 多肽及其在治疗急性肾损伤中的应用
CN109045313B (zh) 一种靶向her2的d型多肽放射性药物及制备方法
CN103833829A (zh) 一种放射性18F标记的靶向肿瘤血管Anxa1显像药物18F-AL-NOTA-IF7及其制备方法
US11254706B2 (en) Peptide and its derivatives capable of inhibiting replication of hepatitis V virus in human adipose-derived stem cells and hepatocytes
Abbood Insights into Therapeutic Peptides and their Quality Control
Honarvar et al. Evaluation of backbone-cyclized HER2-binding 2-helix Affibody molecule for In Vivo molecular imaging
CN104163852A (zh) 与人mhc-i类分子结合的ecm1多肽表位
van Duijnhoven et al. In vivo biodistribution of radiolabeled MMP‐2/9 activatable cell‐penetrating peptide probes in tumor‐bearing mice
KR101523686B1 (ko) 췌도 이미징용 분자 프로브 및 그 사용
Maschauer et al. In vivo monitoring of the antiangiogenic effect of neurotensin receptor-mediated radiotherapy by small-animal positron emission tomography: a pilot study
WO2006028993A2 (en) Assessment of cancer susceptibility to molecular targeted therapy by use of recombinant peptides
WO2007011680A2 (en) Ligands to radiation-induced molecules
CN102596259A (zh) 胰岛成像用分子探针及其使用
JP6986516B2 (ja) イメージング目的のためのキレート部分を含む選択的グルカゴン受容体アゴニスト
Rangger et al. Design and evaluation of novel radiolabelled VIP derivatives for tumour targeting
KR102069104B1 (ko) 폴리펩티드 및 이미징 방법
AU2009286244B2 (en) Radiolabeled annexins
TW201637666A (zh) 能夠抑制ｃ型肝炎病毒於人類脂肪幹細胞及肝細胞複製的肽及其衍生物